Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast... Over the last 20 years, treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer has considerably improved. The development and addition of (neo)adjuvant trastuzumab to chemotherapy in patients with early HER2+ breast cancer (EHBC) has been shown to provide improvements in both disease-free survival (DFS) and overall survival, with some patients having a good prognosis being candidates for chemotherapy de-escalation strategies. However, despite such promising clinical outcomes, a significant proportion of patients still recur calling for the development of new preventive approaches. To this aim, the use of (neo)adjuvant trastuzumab for longer than one year or followed by lapatinib were tested without additional clinical improvement. Based on more recent advances, therapeutic strategies for patients with HER2+ tumours are now incorporating the use of newer (neo)adjuvant treatments, such as pertuzumab and trastuzumab emtansine, which have shown to further improve the invasive DFS (iDFS) benefit gained with trastuzumab. In this context, the tyrosine kinase inhibitor neratinib is approved in Europe for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2+ breast cancer who completed adjuvant trastuzumab-based therapy less than one year ago. Clinical data have demonstrated that neratinib significantly improves iDFS when used for the total recommended duration of 12 months. This review paper provides an overview of the treatment of patients with EHBC, with a focus on the post-trastuzumab use of neratinib. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

Download PDF
13 pages

Loading next page...
 
/lp/springer-journals/how-to-optimise-extended-adjuvant-treatment-with-neratinib-for-fkqK5e7IgS
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2021
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-021-00153-5
Publisher site
See Article on Publisher Site

Abstract

Over the last 20 years, treatment of patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer has considerably improved. The development and addition of (neo)adjuvant trastuzumab to chemotherapy in patients with early HER2+ breast cancer (EHBC) has been shown to provide improvements in both disease-free survival (DFS) and overall survival, with some patients having a good prognosis being candidates for chemotherapy de-escalation strategies. However, despite such promising clinical outcomes, a significant proportion of patients still recur calling for the development of new preventive approaches. To this aim, the use of (neo)adjuvant trastuzumab for longer than one year or followed by lapatinib were tested without additional clinical improvement. Based on more recent advances, therapeutic strategies for patients with HER2+ tumours are now incorporating the use of newer (neo)adjuvant treatments, such as pertuzumab and trastuzumab emtansine, which have shown to further improve the invasive DFS (iDFS) benefit gained with trastuzumab. In this context, the tyrosine kinase inhibitor neratinib is approved in Europe for the extended adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2+ breast cancer who completed adjuvant trastuzumab-based therapy less than one year ago. Clinical data have demonstrated that neratinib significantly improves iDFS when used for the total recommended duration of 12 months. This review paper provides an overview of the treatment of patients with EHBC, with a focus on the post-trastuzumab use of neratinib.

Journal

Oncology and Therapy – Springer Journals

Published: Dec 1, 2021

Keywords: Adjuvant treatment; Early breast cancer; Efficacy; Extended treatment; Human epidermal growth factor receptor 2-positive; Hormone receptor-positive; Neratinib; Tolerability; Trastuzumab; Tyrosine kinase inhibitor

References

  • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    Piccart-Gebhart, MJ; Procter, M; Leyland-Jones, B
  • Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
    Perez, EA; Romond, EH; Suman, VJ
  • Neratinib for the treatment of early-stage HER2-positive breast cancer
    Miles, J; White, Y
  • Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    Slamon, DJ; Godolphin, W; Jones, LA
  • Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
    Wolff, AC; Hammond, ME; Hicks, DG
  • Repeated observation of breast tumor subtypes in independent gene expression data sets
    Sorlie, T; Tibshirani, R; Parker, J
  • Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers
    Chia, SK; Norris, B; Speers, C
  • 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
  • Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer
    von Minckwitz, G; Procter, M; de Azambuja, E
  • Updated results from the international phase III ALTTO trial (BIG 2–06/Alliance N063D)
  • Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
    Gianni, L; Pienkowski, T; Im, YH
  • Trastuzumab emtansine for residual invasive HER2-positive breast cancer
    von Minckwitz, G; Huang, CS; Mano, MS
  • Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer
  • Interim overall survival analysis of APHINITY (BIG 4–11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer
    Piccart, M; Procter, M; Fumagalli, D
  • Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
    Untch, M; Geyer, CE; Huang, CS
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
    Cortazar, P; Zhang, L; Untch, M
  • Pathologic complete response (pCR) and prognosis following neoadjuvant chemotherapy plus anti-HER2 therapy of HER2-positive early breast cancer (EBC)
    Loibl, S; Untch, M; Buyse, M
  • Pathways to breast cancer recurrence
    Ahmad, A
  • Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831
    Romond, EH; Suman, V; Jeong, J-H
  • Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
    Pegram, M
  • Advances in the management of HER2-positive early breast cancer
    Baselga, J; Coleman, RE; Cortés, J; Janni, W
  • Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
    Kourie, HR; El Rassy, E; Clatot, F; de Azambuja, E; Lambertini, M
  • Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
    Martin, M; Holmes, FA; Ejlertsen, B
  • Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
  • Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial
    Mortimer, J; Di Palma, J; Schmid, K; Ye, Y; Jahanzeb, M
  • Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
    Cardoso, F; Kyriakides, S; Ohno, S
  • Breast cancer, version 32020, NCCN clinical practice guidelines in oncology
    Gradishar, WJ; Anderson, BO; Abraham, J
  • Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update
    Denduluri, N; Chavez-MacGregor, M; Telli, ML
  • Patient perspectives on HER2+ breast cancer recurrence: results from an online patient survey
    Jenkins, M
  • Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient outcomes
    Martin, M; Gnant, MI; Ejlertsen, B
  • Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects
    Hartmann, JT; Haap, M; Kopp, HG; Lipp, HP
  • Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial
    Barcenas, CH; Hurvitz, SA; Di Palma, JA